Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214779 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Phase 3 study of Ovarian Cancer, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
- 20
- Study locations
NCT07214779: Recruiting Phase 3 study of Ovarian Cancer, sponsored by Incyte Corporation.
NCT07214779 is a Phase 3 study of Ovarian Cancer that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 466 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214779, a Phase 3 study of Ovarian Cancer, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Primary Outcome
Defined as the time from the date of randomization until the earliest date of disease progression as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG INCB123667
- DRUG Investigator's choice of chemotherapy
Study Locations (20)
North Carolina
- Levine Cancer Center - Charlotte
- Novant Presbyterian Hospital - Charlotte
- Atrium Health Wake Forest Baptist - Winston-Salem
California
- City of Hope Medical Center - Duarte
- Valkyrie Clinical Trials - Los Angeles
Oregon
- Oncology Associates of Oregon, P.C. - Eugene
- Providence Cancer Institute Franz Clinic - Portland
Pennsylvania
- University of Pittsburgh Cancer Institute Cancer Services - Pittsburgh
- Wellspan Gynecologic Oncology - York
Georgia
- Georgia Cancer Center - Augusta
Illinois
- Northshore University Health System-Evanston Hospital - Evanston
Louisiana
- Women'S Cancer Care - Covington
Maine
- Maine Center For Cancer Medicine - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2029-05-14 |
| Phase | Phase 3 |
What NCT07214779 shows while recruiting
NCT07214779 is an interventional study that assigns participants to a tested intervention. The registered 466 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which INCB123667 is the first listed.
NCT07214779 names 20 study sites across 15 states, led by North Carolina, California, Oregon.
Frequently Asked Questions
What is clinical trial NCT07214779 about?
NCT07214779 is a clinical study titled "Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression". The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
What is the current status of trial NCT07214779?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2025-12-09. Estimated completion is 2029-05-14.
What conditions does trial NCT07214779 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT07214779?
The interventions under investigation include: INCB123667 (DRUG), Investigator's choice of chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07214779?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214779 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Louisiana, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07214779's enrollment target sits among peer trials
466 56th of 322 higher than 267 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
- NCT07055165 · 466 participants · NA
Connect2Care: Prostate Cancer Education and Screenings for African American Men
- NCT06456554 · 467 participants · NA
Acellular Dermal Matrix Investigation in Breast Reconstruction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI